CO6481011A2 - Derivados de piridino- piridinonas, su preparación y su aplicación en terapéutica - Google Patents

Derivados de piridino- piridinonas, su preparación y su aplicación en terapéutica

Info

Publication number
CO6481011A2
CO6481011A2 CO12084563A CO12084563A CO6481011A2 CO 6481011 A2 CO6481011 A2 CO 6481011A2 CO 12084563 A CO12084563 A CO 12084563A CO 12084563 A CO12084563 A CO 12084563A CO 6481011 A2 CO6481011 A2 CO 6481011A2
Authority
CO
Colombia
Prior art keywords
group
cycle
alkyl group
atom
links
Prior art date
Application number
CO12084563A
Other languages
English (en)
Inventor
Gilbert Lassalle
Valerie Martin
Challier Cecile Volle
Gary Mccort
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42133583&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6481011(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CO6481011A2 publication Critical patent/CO6481011A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La invención se refiere (i) a derivados de piridino-piridinonas que responden a la fórmula (I) : en la que R1 representa un átomo de hidrógeno o un grupo alquilo(C1-C4); R2 representa un grupo -(CH2)n'-B donde n'=0, 1, 2, 3 o 4 y B representa un grupo cicloalquilo(C3-C5), un grupo alquilo(C1-C4) o un grupo alcoxi(C1-C4); Y, Z, Y y W representan, independientemente entre sí un grupo -CH-, un átomo de carbono, un heteroátomo o ausencia de átomo, entendiéndose que el ciclo, en el que están comprendidos V, W, Y y Z es un ciclo que comprende 5 o 6 eslabones, entendiéndose que las líneas discontinuas en dicho ciclo indican que el ciclo resultante es un ciclo aromático y entendiéndose que dicho ciclo comprende 0, 1 ó 2 heteroátomos; R3 y R4 representan, independientemente entre sí, grupos idénticos o diferentes, elegidos entre un átomo de hidrógeno; y un grupo alquilo(C1-C4) lineal o forman junto con el carbono al que están unidos un grupo cicloalquilo(C3-C5); m es un número entero igual a 1, 2, 3 ó 4; R5 representa un átomo de hidrógeno o un grupo alquilo(C1-C4); R6 representa un grupo -(CH2)n-L en el que n= 0, 1, 2 ó 3, y L es un grupo seleccionado entre arilos de 6 átomos de carbono, heteroarilo de 5 ó 6 eslabones, heterociclos saturados que comprenden 5, 6 ó 7 eslabones o forman junto con el átomo de nitrógeno al que están unidos un grupo heterociclo, (ii) a su preparación y (iii) a su aplicación en terapéutica como inhibidores de la actividad quinasa de los receptores de los ligandos PDGFs y/o de los receptores del ligando FLT3.
CO12084563A 2009-11-23 2012-05-23 Derivados de piridino- piridinonas, su preparación y su aplicación en terapéutica CO6481011A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0905602A FR2952934B1 (fr) 2009-11-23 2009-11-23 Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
CO6481011A2 true CO6481011A2 (es) 2012-07-16

Family

ID=42133583

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12084563A CO6481011A2 (es) 2009-11-23 2012-05-23 Derivados de piridino- piridinonas, su preparación y su aplicación en terapéutica

Country Status (27)

Country Link
US (1) US8623893B2 (es)
EP (1) EP2504338B1 (es)
JP (1) JP2013511501A (es)
KR (1) KR20120099732A (es)
CN (1) CN102762558A (es)
AR (1) AR079077A1 (es)
AU (1) AU2010320692A1 (es)
BR (1) BR112012012403A2 (es)
CA (1) CA2781935A1 (es)
CL (1) CL2012001322A1 (es)
CO (1) CO6481011A2 (es)
CR (1) CR20120261A (es)
DO (1) DOP2012000136A (es)
EA (1) EA201290383A1 (es)
EC (1) ECSP12011916A (es)
FR (1) FR2952934B1 (es)
GT (1) GT201200154A (es)
IL (1) IL219888A0 (es)
MA (1) MA33819B1 (es)
MX (1) MX2012005988A (es)
NI (1) NI201200095A (es)
NZ (1) NZ600108A (es)
PE (1) PE20121338A1 (es)
TN (1) TN2012000229A1 (es)
TW (1) TWI476197B (es)
UY (1) UY33049A (es)
WO (1) WO2011061458A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
SI2874625T1 (sl) * 2012-07-17 2017-10-30 Sanofi Uporaba inhibitorjev VEGFR-3 za zdravljenje hepatoceličnega karcinoma
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CA3037369A1 (en) 2016-09-18 2018-03-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Yap1 inhibitors that target the interaction of yap1 with oct4
EP3706740A4 (en) * 2017-11-06 2021-07-28 Suzhou Pengxu Pharmatech Co., Ltd. METHOD FOR MANUFACTURING ACALABRUTINIB
JP7319977B2 (ja) * 2017-12-06 2023-08-02 リン バイオサイエンス，インコーポレイテッド チューブリン阻害剤
PE20211450A1 (es) 2018-03-14 2021-08-05 H Lee Moffitt Cancer Ct & Res Inhibidores de yap1 que dirigen la interaccion de yap1 con oct4

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4323574B2 (ja) * 1995-12-13 2009-09-02 大日本住友製薬株式会社 抗腫瘍剤
US5994367A (en) * 1997-03-07 1999-11-30 The University Of North Carolina At Chapel Hill Method for treating tumors using 2-aryl-naphthyridin-4-ones
JP3739916B2 (ja) * 1997-12-02 2006-01-25 第一製薬株式会社 サイトカイン産生阻害剤
ES2247325T3 (es) * 2001-05-24 2006-03-01 MERCK FROSST CANADA & CO. Inhibidores de 1-biaril-1,8-naftiridin-4-ona fosfodiesterasa-4.
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
AU2003290699B2 (en) * 2002-11-13 2009-08-27 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
GB0321621D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
US20080234263A1 (en) 2003-09-16 2008-09-25 Laurent Francois Andre Hennequin Quinazoline Derivatives
WO2005091857A2 (en) * 2004-03-12 2005-10-06 Bayer Pharmaceuticals Corporation 1,6-naphthyridine and 1,8-naphthyridine derivatives and their use to treat diabetes and related disorders
WO2007113565A1 (en) * 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives as anti-cancer agents
WO2007113548A1 (en) * 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives
CA2666116A1 (en) * 2006-10-16 2008-04-24 Novartis Ag Phenylacetamides useful as protein kinase inhibitors
EP2139888A2 (en) * 2007-03-28 2010-01-06 Array Biopharma, Inc. Imidazoý1,2-a¨pyridine compounds as receptor tyrosine kinase inhibitors
FR2917412B1 (fr) 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique
FR2917413B1 (fr) 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique
FR2933700B1 (fr) 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2954943B1 (fr) 2010-01-07 2013-03-01 Sanofi Aventis Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors

Also Published As

Publication number Publication date
IL219888A0 (en) 2012-07-31
WO2011061458A1 (fr) 2011-05-26
CL2012001322A1 (es) 2012-08-17
FR2952934A1 (fr) 2011-05-27
PE20121338A1 (es) 2012-10-15
FR2952934B1 (fr) 2012-06-22
ECSP12011916A (es) 2012-07-31
AR079077A1 (es) 2011-12-21
US20130005724A1 (en) 2013-01-03
US8623893B2 (en) 2014-01-07
MX2012005988A (es) 2012-09-07
KR20120099732A (ko) 2012-09-11
TWI476197B (zh) 2015-03-11
UY33049A (es) 2011-06-30
AU2010320692A1 (en) 2012-06-14
JP2013511501A (ja) 2013-04-04
DOP2012000136A (es) 2012-08-15
TW201121971A (en) 2011-07-01
BR112012012403A2 (pt) 2017-10-10
CR20120261A (es) 2012-07-04
TN2012000229A1 (fr) 2013-12-12
EP2504338B1 (fr) 2015-03-18
MA33819B1 (fr) 2012-12-03
EP2504338A1 (fr) 2012-10-03
CN102762558A (zh) 2012-10-31
NI201200095A (es) 2012-08-20
EA201290383A1 (ru) 2013-01-30
NZ600108A (en) 2013-06-28
GT201200154A (es) 2013-11-07
CA2781935A1 (fr) 2011-05-26

Similar Documents

Publication Publication Date Title
CO6481011A2 (es) Derivados de piridino- piridinonas, su preparación y su aplicación en terapéutica
ECSP13012363A (es) Derivados de imidazopiridina, su procedimiento de preparación y su aplicación en terapéutica
NI201200191A (es) Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
AR089774A1 (es) Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
AR088829A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
UY29037A1 (es) Nuevos derivados de urea cíclicos sustituidos con heterociclo, su preparación y su uso farmacéutico como inhibidores de quinasa
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
ECSP099216A (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY32801A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CO6150150A2 (es) Derivados de 7-alquinil-1,8-naftiridonas su prepacion y su aplicacion en terapeutica
CO6150147A2 (es) Derivados de 5,6-bisaril-2-piridin-carboxamida su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii
AR053340A1 (es) Derivados de trifluormetilbenzamida y sus usos terapeuticos
CO6551705A2 (es) Derivados de 3.4.4a.10b- tetrahidro-1h-tiopirano-[4.3-c]- isoquinolina
SV2009003348A (es) Nuevos derivados triciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen
AR096040A1 (es) Compuestos sustituidos y condensados de pirimidina como inhibidores de pde4b
NI201000215A (es) NUEVOS DERIVADOS DE (PIPERAZINILO CON ENLACES PUENTE )- 1 - ALCANONA Y SU UTILIZACIÓN COMO INHIBIDORES DE p75.
MA32342B1 (fr) Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CU20130037A7 (es) Nuevos derivados dihidrobenzoxatiazepinas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR072623A1 (es) Derivados de pirrolidinil-alquil-amida su preparacion y su aplicacion terapeutica comoligandos de los receptores de ccr3
ECSP12011971A (es) NUEVOS DERIVADOS (HETEROCICLO-TETRAHIDRO-PIRIDIN)-(PIPERAZINIL)-1-ALCANONA Y (HETEROCICLO-DIHIDRO-PIRROLIDIN)-(PIPERAZINIL)-1-ALCANONA Y SU UTILIZACIÓN COMO INHIBIDORES DE p75
UY32575A (es) Derivados de 1h-pirazolo[4,3-c]isoquinoleínas, su preparación y su aplicación en terapéutica
CU23563A3 (es) Derivados de (tio) carbamoil-ciclohexano como antagonistas del receptor d3/d2
CR11599A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FC Application refused